Skip to main content
About HEC About HEC Faculty & Research Faculty & Research Master’s programs Master’s programs MBA Programs MBA Programs PhD Program PhD Program Executive Education Executive Education Summer School Summer School HEC Online HEC Online About HEC Overview Overview Who
We Are Who
We Are
Egalité des chances Egalité des chances Career
Center Career
International International Campus
Life Campus
Sustainability Sustainability Diversity
& Inclusion Diversity
& Inclusion
Stories Stories The HEC
Foundation The HEC
Coronavirus Coronavirus
Faculty & Research Overview Overview Faculty Directory Faculty Directory Departments Departments Centers Centers Chairs Chairs Knowledge Knowledge Master’s programs Master in
Management Master in
MSc International
Finance MSc International
Masters Specialized
programs X-HEC
programs Dual-Degree
students Visiting
Certificates Certificates Student
Life Student
Stories Student
MBA Programs MBA MBA Executive MBA Executive MBA TRIUM EMBA TRIUM EMBA PhD Program Overview Overview HEC Difference HEC Difference Program details Program details Research areas Research areas HEC Community HEC Community Placement Placement Job Market Job Market Admissions Admissions Financing Financing Executive Education Executive Masters Executive Masters Executive Certificates Executive Certificates Executive short programs Executive short programs Online Online Companies Companies Executive MBA Executive MBA Summer School Youth Programs Youth Programs Summer programs Summer programs HEC Online Overview Overview Degree Program Degree Program Executive certificates Executive certificates MOOCs MOOCs Summer Programs Summer Programs
PhD Program

PhD Thesis defence - Ivan Lugovoi

PhD - image - L. Lugovoi

Congratulations to Dr Ivan Lugovoi, Information Systems and Operations Management specialization, who successfully defended his thesis at HEC Paris, on December 6, 2019.

Thesis Topic: Process Innovation in Pharmaceutical Industry

Supervisor: Professor Dimitrios Andritsos, HEC Paris

Members of the jury:

  • M. Jürgen MIHN, Professor, INSEAD                             
  • Mrs Xiaowei LUO, Professor, INSEAD                             
  • Mrs Svenja SOMMER, Associate Professor, HEC PARIS


Abstract: Process innovation is commonly claimed to be a major source of competitive advantage for firms. Despite this perceived influence, it has received substantially less attention than product innovation and much uncertainty re-mains about its true association with firm performance. The main focus of this study is on the relationship between a pharmaceutical manufacturing firm’s process-innovation portfolio and its economic performance. Through a collaboration with expert patent attorneys, a unique longitudinal dataset was developed, that combines secondary data and evaluations of a firm’s portfolio of process patents along three key dimensions: novelty, scope, and locus. I find positive association between overall process innovation and firm performance. Econometric analyses of the large-scale longitudinal dataset suggest that ownership of a portfolio of patented process innovations for the production of a given drug is associated with a market share (for that drug) that is on average 5.4% higher relative to non-process-innovative competitors. When differentiating between dimensions of process innovation, results further suggest that high novelty is beneficial, and complemented by a broad scope, but only for patents applying to the later phase of the pharmaceutical manufacturing process. The results of this study reconcile differences in the organizational learning, strategy, and operations management literatures. The study identifies both advantages and disadvantages of the three types of technological experiences: focal, related, and unrelated. I find that technological experience with the focal product is positively associated with the ability of a firm to process innovate, resulting in the inventions of medium Novelty and broad Scope. By contrast, I find that technological experience with related products is negatively associated with the ability of a firm to process innovate, resulting in the inventions of low Novelty and broad Scope. Likewise, technological experience with unrelated products is also negatively associated with an ability of a firm to process innovate, though it results in the inventions of high Novelty and narrow Scope.